SJS/TEN 2017: Building multidisciplinary networks to drive science and translation Journal Article


Authors: White, K. D.; Abe, R.; Ardern-Jones, M.; Beachkofsky, T.; Bouchard, C.; Carleton, B.; Chodosh, J.; Cibotti, R.; Davis, R.; Denny, J. C.; Dodiuk-Gad, R. P.; Ergen, E. N.; Goldman, J. L.; Holmes, J. H. 4th; Hung, S. I.; Lacouture, M. E.; Lehloenya, R. J.; Mallal, S.; Manolio, T. A.; Micheletti, R. G.; Mitchell, C. M.; Mockenhaupt, M.; Ostrov, D. A.; Pavlos, R.; Pirmohamed, M.; Pope, E.; Redwood, A.; Rosenbach, M.; Rosenblum, M. D.; Roujeau, J. C.; Saavedra, A. P.; Saeed, H. N.; Struewing, J. P.; Sueki, H.; Sukasem, C.; Sung, C.; Trubiano, J. A.; Weintraub, J.; Wheatley, L. M.; Williams, K. B.; Worley, B.; Chung, W. H.; Shear, N. H.; Phillips, E. J.
Article Title: SJS/TEN 2017: Building multidisciplinary networks to drive science and translation
Abstract: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening, immunologically mediated, and usually drug-induced disease with a high burden to individuals, their families, and society with an annual incidence of 1 to 5 per 1,000,000. To effect significant reduction in short- and long-term morbidity and mortality, and advance clinical care and research, coordination of multiple medical, surgical, behavioral, and basic scientific disciplines is required. On March 2, 2017, an investigator-driven meeting was held immediately before the American Academy of Dermatology Annual meeting for the central purpose of assembling, for the first time in the United States, clinicians and scientists from multiple disciplines involved in SJS/TEN clinical care and basic science research. As a product of this meeting, this article summarizes the current state of knowledge and expert opinion related to SJS/TEN covering a broad spectrum of topics including epidemiology and pharmacogenomic networks; clinical management and complications; special populations such as pediatrics, the elderly, and pregnant women; regulatory issues and the electronic health record; new agents that cause SJS/TEN; pharmacogenomics and immunopathogenesis; and the patient perspective. Goals include the maintenance of a durable and productive multidisciplinary network that will significantly further scientific progress and translation into prevention, early diagnosis, and management of SJS/TEN. © 2017 American Academy of Allergy, Asthma & Immunology
Keywords: clinical feature; review; drug safety; nonhuman; t cells; quality of life; morbidity; patient assessment; practice guideline; food and drug administration; drug hypersensitivity; cost effectiveness analysis; psychological aspect; drug surveillance program; early diagnosis; urogenital tract disease; geriatrics; pediatrics; stevens johnson syndrome; toxic epidermal necrolysis; rare disease; immunopathogenesis; networks; hla; health care management; human immunodeficiency virus infected patient; pregnant woman; pharmacogenomics; mortality rate; singapore; interdisciplinary research; human; electronic health record; granulysin; pharmacovigilance; stevens-johnson; pharmacogenetic testing
Journal Title: Journal of Allergy and Clinical Immunology: In Practice
Volume: 6
Issue: 1
ISSN: 2213-2198
Publisher: Elsevier B.V.  
Date Published: 2018-01-01
Start Page: 38
End Page: 69
Language: English
DOI: 10.1016/j.jaip.2017.11.023
PROVIDER: scopus
PUBMED: 29310768
PMCID: PMC5857362
DOI/URL:
Notes: Review -- Export Date: 1 March 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mario E Lacouture
    457 Lacouture